| Literature DB >> 33490645 |
Hidehiko Kikuchi1, Kaori Harata1, Harishkumar Madhyastha2, Futoshi Kuribayashi3.
Abstract
Ellagitannins (esters composed of glucose and ellagic acid) are hydrolyzed to generate ellagic acid in gut followed by conversion of ellagic acid to urolithins such as urolithin A by intestinal bacteria. Since urolithins are absorbed by gut easier than ellagitannins and ellagic acid, and show various physiological activities (e.g. anti-cancer, anti-cardiovascular disease, anti-diabetes mellitus, anti-obesity and anti-Alzheimer disease activities), they are expected as excellent health-promoting phytochemicals. Here, using human monoblast U937 cells, we investigated the effect of ellagic acid and urolithin A on the superoxide anion (O2 -)-generating system of phagocytes, which is consisted of five specific protein factors (membrane proteins: p22-phox and gp91-phox, cytosolic proteins: p40-phox, p47-phox and p67-phox). Twenty micromolar of urolithin A enhanced the all-trans retinoic acid (ATRA)-induced O2 --generating activity (to ~175%) while 20 μM ellagic acid inhibited the ATRA-induced O2 --generating activity (to ~70%). Semiquantitative RT-PCR showed that transcription level of gp91-phox was certainly decreased (to ~70%) in ATRA plus ellagic acid-treated cells, while that of gp91-phox was significantly increased (to ~160%) in ATRA plus urolithin A-treated cells. Chromatin immunoprecipitation assay suggested that urolithin A enhanced acetylations of Lys-9 residues of histone H3 within chromatin surrounding the promoter region of gp91-phox gene, but ellagic acid suppressed the acetylations. Immunoblotting also revealed that ATRA plus urolithin A-treatment up-regulated protein levels of p22-phox (to ~160%) and gp91-phox (to ~170%) although ATRA plus ellagic acid-treatment down-regulated protein levels of p22-phox (to ~70%) and gp91-phox (to ~60%). These results suggested that conversion of ellagic acid to urolithin A in gut may bring about reverse effects on the gp91-phox gene expression, resulting in opposite alterations in O2 --generating activity of intestinal macrophages.Entities:
Keywords: ATRA, all-trans retinoic acid; All-trans retinoic acid; ChIP, chromatin immunoprecipitation; Ellagic acid; H3K14, Lys-14 residues of histone H3; H3K9, Lys-9 residues of histone H3; O2−, superoxide anion; PMA, phorbol 12-myristate 13-acetate; Superoxide; U937; Urolithin A; gp91-phox
Year: 2021 PMID: 33490645 PMCID: PMC7806786 DOI: 10.1016/j.bbrep.2020.100891
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1Influences of ellagic acid and urolithin A on the ATRA-induced O2−-generating activity in U937 cells. (A) Conversion scheme of ellagic acid to urolithin A by intestinal bacteria. (B) Influences of ATRA plus ellagic acid or urolithin A on induction of the O2−-generating activity. O2− generation was determined after culture of the cells at 37 °C for 48 h in the absence (None) or presence of each agent (ATRA, ATRA plus ellagic acid or ATRA plus urolithin A) as in “Materials and methods.” Cells (1 × 106 cells/ml) were stimulated with 200 ng/ml PMA at 37 °C. PMA-induced chemiluminescences were measured at 10 min after stimulation. Data represent the averages of three separate experiments and error bars indicate standard deviation. **, P < 0.01 compared with the data of ATRA-treated cells; n. s., not significant.
Fig. 2Influences of co-treatment with ATRA and ellagic acid or urolithin A on transcription of the O2−-generating system-related genes. Total RNAs were extracted from ATRA-treated, ATRA plus ellagic acid-treated (A), and ATRA plus urolithin A-treated (B) U937 cells, and mRNA levels of p22-phox, gp91-phox, p40-phox, p47-phox and p67-phox were determined by semiquantitative RT-PCR as in “Materials and methods.” Data calibrated with the internal controls are indicated as percentages of control values (100%) obtained from ATRA-treated U937 cells and represent the averages of three separate experiments. Error bars indicate standard deviation. **, P < 0.01 compared with the data of ATRA-treated cells.
Fig. 3Influences of co-treatment with ATRA and ellagic acid or urolithin A on acetylation levels of H3K9 and H3K14 residues within chromatin surrounding the promoter regions of gp91-phox gene. (A) Typical patterns of PCR. ChIP assay was performed as in “Materials and Methods”. PCR products were subjected to 2% agarose gel electrophoresis and analyzed using a luminescent image analyzer as described [16,17]. (B) Quantitative analysis. Cross-linked chromatins of ATRA-treated, ATRA plus ellagic acid-treated and ATRA plus urolithin A-treated U937 cells were co-precipitated by antibodies specific for acetylated H3K9 and H3K14 residues. PCRs were performed as in “Materials and methods.” Data are indicated as percentages of control values (100%) obtained from ATRA-treated U937 cells and represent the averages of three separate experiments. Error bars indicate standard deviation. *, P < 0.05; **, P < 0.01 compared with the data of ATRA-treated cells.
Fig. 4Influences of co-treatment with ATRA and ellagic acid or urolithin A on protein levels of the O2−-generating system-related factors. (A) Typical immunoblot profiles. Cytosolic (for p40-phox, p47-phox and p67-phox) and membrane (for p22-phox and gp91-phox) fractions were prepared from ATRA-treated (lane 1), ATRA plus ellagic acid-treated (lane 2) and ATRA plus urolithin A-treated (lane 3) U937 cells, and protein levels were determined by immunoblotting as in “Materials and methods.” Human β-actin (for cytosolic fractions) and Na+/K+-ATPase (for membrane fractions) were used as controls. Quantitative data of ATRA plus ellagic acid-treated (B) and ATRA plus urolithin A-treated (C) U937 cells are indicated as percentages of control values (100%) obtained from ATRA-treated U937 cells, and represent the averages of three separate experiments. Error bars indicate standard deviation. **, P < 0.01 compared with the data of ATRA-treated cells.